Analysis of Early Healing of Sutures in Periodontal Surgery
Launched by ANA MARÍA GARCÍA DE LA FUENTE · Dec 30, 2023
Trial Information
Current as of July 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
A total of 60 patients will be included, where the unit of study will be each stitch, among the patients attending the Dental Clinic Service of the University of the Basque Country (UPV/EHU) who require surgical periodontal treatment.
The patients will be randomly divided into two groups: the control group using a conventional suture (n=30), and the test group using a suture coated with chlorhexidine diacetate (n=30).
Suture in the control group: absorbable suture of polyglactin 910 coated with polyglactin 370 + calcium stearate without chlorhexidine (NOVOSYN) Suture in the test group: ab...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients ≥ 18 years-old
- • Patients who have completed the basic periodontal phase and require surgical periodontal treatment for periodontal disease control.
- • Plaque index (O'Leary et al.,1972) ≤20%.
- • Bleeding index (Ainamo \& Bay,1975) ≤20%.
- Exclusion Criteria:
- • Patients with systemic conditions contraindicating surgery
- • Patients with allergy to chlorhexidine and/or o-cymen-5-ol
- • Patients allergic to non-steroidal anti-inflammatory drugs (NSAIDs)
- • Pregnant or breastfeeding women
- • Patients with periodontal defects requiring regenerative surgery or mucogingival surgery/periodontal plastic therapy
- • Patients who have taken antibiotics in the last 3months
About Ana María García De La Fuente
Ana María García de la Fuente is a distinguished clinical trial sponsor known for her commitment to advancing medical research and innovation. With a robust background in clinical pharmacology and a keen focus on patient-centric approaches, she has successfully led numerous trials across various therapeutic areas. Her expertise in regulatory compliance and strategic trial design ensures that studies are conducted with the highest ethical standards, prioritizing participant safety and data integrity. Ana María's collaborative leadership style fosters partnerships with research institutions and healthcare professionals, driving the development of groundbreaking therapies that improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leioa, Biscay, Spain
Patients applied
Trial Officials
Ana María García-De-La-Fuente, phD
Study Director
University of the Basque Country (UPV/EHU)
Aitziber Fernández-Jiménez, phD
Principal Investigator
University of the Basque Country (UPV/EHU)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported